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Transbronchial fine needle aspiration (TBNA) is a simple technique
for sampling mediastinal lymph nodes and may provide additional
information in patients with suspected lung cancer. However, the
technique is still under-utilized, and the objective of this study was
to evaluate the value of TBNA as part of an integrated pathway for
the assessment of patients with suspected lung cancer. All patients
referred to the lung cancer services of our institutions were prospec-
tively evaluated. TBNA was performed in all patients with evidence
of mediastinal lymphadenopathy. TBNA of one or more lymph node
sites were performed in 129 of these patients. TBNA was the sole
diagnostic modality in 23% of patients and provided positive staging
information for 49% of patients, with adequate sampling in 71% of
patients. Among patients with mediastinal adenopathy, the number
of patients who required a TBNA performed to diagnose one patient
with malignancy in patients suspected with lung cancer (number
needed to diagnose) was 1.47 (95% confidence interval, 1.47–1.76).
No complications were observed in patients who underwent TBNA.
TBNA improves the diagnostic yield and staging of patients with
lung cancer. Moreover, it is a simple, low-cost, and safe test, which
should be incorporated into the diagnostic pathway of patients with
suspected lung cancer.
Key Words: Lung cancer, Bronchoscopy, Transbronchial fine nee-
dle aspiration, Integrated care pathway.
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Lung cancer is the third most common cause of death in theWestern World among both men and women. In the
United Kingdom, there are more than 35,000 new cases of
lung cancer each year, and the overall prognosis remains
poor. Treatment is dependent on accurate histological or
cytological diagnosis and accurate staging. Lung cancer oc-
curs more frequently in the elderly, and patients also fre-
quently have significant disease morbidity; therefore, it is
important to obtain accurate staging by the least invasive
investigation. Transbronchial needle aspiration (TBNA) via
the rigid bronchoscope was first described in 19491 and was
adapted for the flexible bronchoscope by Wang.2 However,
this technique is still under-utilized despite a number of
reports in the literature. A North American bronchoscopy
survey suggested that only 11.8% of respondents used TBNA
routinely for cases in which malignant disease was suspect-
ed.3 A subsequent survey among pulmonary fellows demon-
strated that the proportion that routinely uses TBNA is still
approximately 10%.4 We prospectively evaluated patients
with suspected lung cancer who underwent flexible bronchos-
copy and evaluated the added value of TBNA in routine
clinical practice.
METHODS
All patients referred to our rapid access clinics (Chelsea
& Westminster Hospital or Royal Brompton Hospital) with
suspected lung cancer were prospectively evaluated. All the
assessments were made as part of the routine clinical evalu-
ation of patients with lung cancer from December 1999
through June 2003. TBNA was performed using a 21-gauge
needle (NAC-1; Olympus, Tokyo, Japan) in all patients who
had mediastinal lymph nodes larger than 10 mm in short axis
on computed tomograms (CT) of the thorax. The procedures
were planned according to the axial CTs of the thorax, and
the nodes that could be sampled were determined. The ac-
cessible sites were right paratracheal nodes, left paratracheal
nodes, anterior carinal nodes, posterior carinal nodes, sub-
carinal nodes, right main bronchial, left main bronchial, right
upper hilar, right lower hilar, sub-subcarinal nodes, and left
lower hilar. TBNA was performed before inspection or sam-
pling of the tracheo-bronchial tree. This was to minimize the
risk of false-positive contamination by malignant cells from
the distal airway. The needle with the protective sheath was
introduced through the bronchoscope channel so that approx-
imately 5 mm of the distal tip was visible. This was apposed
to the airway wall at the desired site and the needle was
inserted perpendicular to the airway wall by a jabbing tech-
nique until the full 13-mm length had penetrated the airway
wall. With the jabbing technique, the bronchoscope position
is fixed, and the needle is pushed perpendicularly through the
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intercartilagenous space by a firm and quick push of the
catheter. The needle was then moved in and out while the
assistant applied constant suction with a 20-ml syringe. Four
passes of the needle were made at each lymph node location.
The aspirated material was spread onto cytology slides, and
smears were prepared for subsequent off-site cytological
examination. Any small pieces of tissue obtained were placed
in formalin for histological analysis.
Accuracy of TBNA was based on the presence of
lymphocytes within the specimen, confirming that the spec-
imen was obtained from lymph node aspiration. Patelli et al.5
suggested that the sample should have at least 30% of
lymphocytes to be considered appropriate, but our view was
that this is an arbitrary number and that the key message is
that a negative result may be a false negative and should be
further investigated. A positive diagnosis for cancer was
based on the presence of carcinoma cells, typically mixed in
with lymphocytes. Samples without malignant cells but with
lymphocytes cannot confidently exclude metastatic disease.
Therefore, patients with a negative diagnosis underwent fur-
ther investigation such as positron emission tomography
(PET) and mediastinoscopy. In eight cases, no further inves-
tigations were performed on the basis of a confident diagnosis
of non-malignant disease. These patients had at least 18
months’ follow-up before they were considered true nega-
tives. Any patients with a final diagnosis of malignant dis-
ease, but a negative TBNA who did not have a mediastinos-
copy (patient refusal or unfit for surgery) were regarded as
false negatives for the purpose of the study.
Statistical Analysis
All patient data for the cohort of 827 patients were
prospectively collected. Descriptive analysis of continuous
variables is presented as means and standard deviations,
whereas nominal variables are presented as medians and
interquartile ranges. The reliability of the diagnostic test was
estimated by calculating the sensitivity, specificity, and pos-
itive and negative predictive values. The number needed to
diagnose (NND) was calculated the same way the number
needed to treat was estimated.6 The NND is the reciprocal of
the fraction of positive tests in the group with the disease
minus the fraction of positive tests in the group without the
disease. Thus NND  1/(Sensitivity – [1 – Specificity]).
RESULTS
During the study period (December 1999 to June 2003),
827 patients were referred to our lung cancer service with
suspected malignancy. Of the 827 patients, 482 (58%) were
male, and the median age was 67.5 years. A final diagnosis of
malignancy was made in 561 of these patients and was
confirmed pathologically in 502 (89%) patients (363 non-
small cell lung cancer, 54 small cell lung cancer, 12 other
primary lung cancers, 15 mesotheliomas, and 58 lung metas-
tases from other primary tumors). A bronchoscopy was per-
formed in 433 patients, and 129 of these patients (30%) also
underwent a TBNA at the same time as their diagnostic
bronchoscopy. The initial CT scan for 128 patients demon-
strated an alternative means of obtaining a diagnosis and
staging information such as pleural aspiration, supraclavic-
ular lymph node biopsy or liver biopsy. For the remaining
266 patients, the initial CT scan was sufficient to exclude
lung cancer.
TBNA was the sole mode of diagnosis for 30 patients
(23%) and provided staging information in 63 patients (49%).
Of these patients, 47 had N2 disease, four had N3 disease,
and 12 had limited-stage small cell lung cancer. All patients
with lymph nodes larger than 10 mm in short axis underwent
TBNA of the enlarged lymph nodes at bronchoscopy, and in
this group, the number of patients who required a TBNA
performed to diagnose one patient with malignancy (NND)
was 1.47 (95% confidence interval [CI] 1.47-1.76) (Table 1).
The diagnostic accuracy of TBNA was 78% (95% CI 70%–
85%) with a sensitivity of 68% (95% CI 59%–78%), and
specificity of 100%. There were 29 false-negative results, and
three of these patients had a final diagnosis of lymphoma.
Sixteen patients underwent a mediastinoscopy, but 13 pa-
tients were either deemed unsuitable for surgical intervention
or refused surgery.
A total of 197 different lymph node groups were
sampled (Table 2). A single lymph node group was sampled
in 52% of patients, two separate lymph node groups were
sampled in 40%, and three or more different lymph node
groups were sampled in 8%. Overall, 71% of lymph nodes
were adequately sampled, and tumor cells were present in
44% of patients (Table 2). Right paratracheal lymph nodes
were most frequently sampled. Adequate sampling, indicated
by the presence of lymphocytes or tumor cells, was achieved
in 72% of the right paratracheal lymph nodes sampled, and
malignant cells were detected in 43%. Subcarinal lymph
nodes were also frequently enlarged, and tumor cells were
found in 50% of nodes sampled. The other more frequently
sampled lymph node station was the anterior carinal node,
with a 35% positive yield for cancer.
Lymph node size was a key determinant of success:
sensitivity was 63% for lymph nodes smaller than 20 mm and
71% for lymph nodes equal to or larger than 20 mm (Table
3). For lymph nodes larger than 20 mm, the NND was only
1.2 (95% CI, 1.2–3.0).
Histological specimens were obtained from 38 lymph
node sites. In this group, the accuracy was higher, 87%
TABLE 1. Characteristics of transbronchial fine needle
aspiration of mediastinal lymph nodes
Disease present Disease absent
TBNA positive 63 0
TBNA negative 29 37
95% confidence
interval
Sensitivity 68% 59%–78%
Specificity 100% 100%
Accuracy 78% 70%–85%
Positive predictive value 100% 95%–100%
Negative predictive value 56% 44%–67%
Number needed to diagnose 1.46 1.46–1.76
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(prevalence 55%, sensitivity 76%). However, the key advan-
tage in these cases was that the pathologist had greater
confidence with the diagnosis, and immunostaining could be
used to further characterize the tumor.
There were no adverse events observed in any patient
who underwent TBNA. Specifically, none of the patients
developed a pneumothorax, pneumomediastinum, or hemor-
rhage (more than 50 ml). Minor bleeding was the only
adverse event attributable to TBNA.
DISCUSSION
TBNA significantly improves the diagnostic yield and
staging information for patients with suspected lung malig-
nancy. Moreover, in this study, we further demonstrated its
safety, cost-effectiveness, and ease of incorporation into an
integrated care pathway for the diagnosis and staging of lung
cancer. Furthermore, the complication rate of TBNA is sig-
nificantly lower than that observed for transbronchial lung
biopsies. In this series of patients, there were no significant
complications. The incidence of pneumothorax, pneumome-
diastinum, and hemorrhage derived from studies in the liter-
ature is low and ranges from 0.05% to 0.2%.1,5,7–17 The
sensitivity and accuracy from our unselected series are
broadly comparable to previously published series.5,7–17 In
our analysis, patients with a negative or inconclusive TBNA
who did not have further surgical assessment were considered
to have false-negative results; hence, the results presented
may be more conservative than the actual findings. Further-
more, in this unselected series of patients, TBNA was per-
formed for all individuals with mediastinal nodes measuring
10 mm or larger, and the prevalence of disease was approx-
imately 60%. In contrast, the only other comparable series
reported a prevalence rate of only 34%.9
The advantages of TBNA are that it can be established
in any bronchoscopy unit with minimal cost and that it can be
performed at the same time as the initial diagnostic bronchos-
copy. Consequently, it can be performed in any individual
who is fit for bronchoscopy and can be incorporated into the
diagnostic pathway without any delays in patient assessment.
It also minimizes the number of investigations that patients
require for both diagnosis and staging. In this cohort, incor-
porating TBNA into the diagnostic bronchoscopy identified
49% of patients who had cancer cells in their mediastinal
lymph nodes aspirates and were therefore spared further,
more hazardous surgical staging investigations. Hence, only
patients with negative sampling required either additional
investigations to confirm malignancy or further clinical fol-
low-up to confirm suspected benign disease.
PET is a useful tool in the staging of patients with lung
cancer. It has a sensitivity of 84% and specificity of 89%, and
with combined CT-PET, the sensitivity improves to 93% and
specificity to 95%.18 However, with respect to the mediasti-
num, there is still a false-positive rate of 10% to 15%.19
Hence, it is strongly advocated that positive results on PET
scanning should be confirmed by cytopathology.20
Endoscopic ultrasound-guided fine needle aspiration
(EUS-FNA) is an alternative technique that allows staging of
the mediastinum.21–24 The yield may be higher than TBNA,
but it is only able to sample nodes that are adjacent to the
esophagus and unable to examine right paratracheal, anterior
carinal, and right main bronchial nodes, as they are not
adjacent to the esophagus, and the ultrasound is unable to
penetrate the air within the trachea. In our unselected cohort,
the latter lymph nodes accounted for more than 50% of
enlarged lymph nodes that were involved by metastatic dis-
ease. Hilar lymph nodes are also inaccessible by EUS-FNA.
The technique also requires a significant capital investment
that includes an ultrasound imaging system (113,000 euros),
a special linear array echo-endoscope (80,000 euros), a radial
echo-endoscope (80,000 euros), specialist cleaning equip-
ment, and considerable staff training. In comparison, TBNA
requires no capital costs other than the special needles (ap-
TABLE 2. Transbronchial fine needle aspiration diagnostic yield according to lymph nodes sampled
Site
Lymph nodes
sampled
Mean size of
node(mm)
Adequate sampling
(tumor/lymphocytes)
Tumor cells
identified Prevalence Sensitivity
Right paratracheal 58 17 72% 43% 66% 68%
Left paratracheal 17 17 47% 41% 83% 60%
Subcarinal 57 18 73% 50% 71% 72%
Anterior carinal 32 17 79% 35% 71% 45%
Posterior carinal 9 18 87% 67% 78% 86%
Right main bronchial 8 18 33% 25% 62% 40%
Left main bronchial 2 17 100% 50% - -
Right hilar 9 14 75% 44% 50% 75%
Left hilar 5 11 100% 20% 80% 25%
Total 197 17 71% 44% 70% 59%
TABLE 3. Yield according to lymph node size
<19 mm >20 mm
Sensitivity (95% CI) 63% (49%–63%) 71% (60%–71%)
Specificity (95% CI) 100% 100%
NND 1.6 (1.6–3.4) 1.2 (1.2–3.0)
CI, confidence interval; NND, number needed to diagnose.
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proximately 44 euros per procedure), and the bronchoscopy
staff require minimal additional training. With EUS-FNA, the
procedure must also be arranged separately from the initial
diagnostic bronchoscopy, and the expertise is currently only
available in some centers.
Eudobronchial ultrasound guided TBNA (EBUS-
TBNA) has a higher yield when all lymph node stations are
considered (58% with conventional TBNA compared with
84% with ultrasound guidance), but there was no statistical
advantage when subcarinal nodes are considered alone (74%
versus 84%).25 Newer integrated bronchoscopes with a linear
array probe built into the bronchoscope allow EBUS-TBNA
of mediastinal lymph nodes under direct ultrasound control,
but this has the same logistical and financial limitations as
EUS-FNA.26,27 The sensitivity of EBUS-TBNA ranges from
85% to 96%.26–28 Although image-guided TBNA is superior
to conventional TBNA, it is only available in a limited
number of centers worldwide.
Mediastinoscopy remains the gold standard for staging
the mediastinum but requires general anesthesia and still
carries the risk of morbidity.29 The complication rate is
approximately 2.5% and includes hemorrhage, pneumotho-
rax, mediastinitis, esophageal perforation, trauma to the azy-
gos vein, and recurrent laryngeal nerve. It is therefore usually
reserved for patients who are considered potential surgical
candidates. Furthermore, TBNA is able to access more deeply
placed nodes, such as the posterior carinal nodes and hilar
nodes. We therefore suggest that all patients undergoing
bronchoscopy for suspected lung cancer be considered for
TBNA if there is CT or PET evidence of mediastinal disease.
A combination of EUS-FNA and EBUS-TBNA should be
used where the services are available, but, at the very least,
blind TBNA should be considered for patients with medias-
tinal adenopathy.
In conclusion, TBNA is a safe technique that can be
easily performed at the time of a diagnostic bronchoscopy.
The procedure is low cost, not least as it obviates the need for
mediastinoscopy in 50% of cases, and significantly improves
the diagnostic yield and staging information for patients with
suspected malignancy.
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